Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Grace Therapeutics, Inc. (GRCE)

2.1400 +0.0400 (+1.90%)
At close: September 2 at 4:00:01 PM EDT
2.1382 -0.0018 (-0.08%)
Pre-Market: 7:57:29 AM EDT
Chart Range Bar
Loading chart for GRCE
  • Previous Close 2.1000
  • Open 2.1900
  • Bid 1.5100 x 200
  • Ask 2.8000 x 200
  • Day's Range 2.0969 - 2.1900
  • 52 Week Range 1.7900 - 5.1800
  • Volume 48,977
  • Avg. Volume 220,361
  • Market Cap (intraday) 45.017M
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1700
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.05

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

www.gracetx.com

5

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GRCE
38.15%
S&P 500 (^GSPC)
11.99%

1-Year Return

GRCE
28.43%
S&P 500 (^GSPC)
19.50%

3-Year Return

GRCE
1.90%
S&P 500 (^GSPC)
69.77%

5-Year Return

GRCE
85.96%
S&P 500 (^GSPC)
68.98%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue --
Earnings -1.18M
Profit Margin 0.00%

Q2

FY26

Q3

FY26

Q4

FY26

-2M
-2M
-1M
-500K
0
0.0%

Analyst Insights

View More

Analyst Price Targets

4.02
6.05 Average
2.1400 Current
8.07 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/24/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 12 -> 8

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    44.39M

  • Enterprise Value

    30.63M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.92

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -10.81%

  • Return on Equity (ttm)

    -36.19%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -20.22M

  • Diluted EPS (ttm)

    -1.1700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.76M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.1400 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: